SecurityUNIT / Uniti Group Inc. (20341J104)
President and CEOGunderman Kenny
IndustryReal Estate Investment Trusts
Institutional Owners15
Institutional Shares13,593,262 - 7.74%
Common Shares Outstanding175,703,882 shares (as of 2018-03-31)
Institutional Value$ 2,977,464,000 USD
Related CSAL / Communications Sales & Leasing, Inc.

Institutional Stock Ownership and Shareholders()

UNIT / Uniti Group Inc. Institutional Ownership

Uniti Group Inc. (NASDAQ:UNIT) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13,593,262 shares. Largest shareholders include BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., Toscafund Asset Management LLP, BlackRock Investment Management, LLC, Group One Trading, L.p., Group One Trading, L.p., PVG Asset Management, BlackRock Group LTD, Hbk Investments L P, and BlackRock Advisors LLC.
Uniti Group Inc. (NASDAQ:UNIT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/unit"><img src="https://images.fintel.io/us-unit-so.png" alt="UNIT / Uniti Group Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-14 13F-HR PVG Asset Management 119,730 104,624 -12.62 3,460,197 2,658,495 -23.17
2017-01-13 13F-HR MetLife Securities, Inc 15,530 11,378 -26.74 488 290 -40.57
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 843 462 -45.20 44 31 -29.55
2017-02-10 13F-HR BlackRock Advisors LLC 70,540 75,578 7.14 2,216 1,920 -13.36
2017-05-01 13F-HR Spot Trading L.L.C Call 19,600 0 -100.00 498 0
2017-02-10 13F-HR BlackRock Group LTD 100,436 102,941 2.49 3,153 2,616 -17.03
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 28,800 324,000 1,025.00 512 5,265 928.32
2017-02-14 13F-HR STEADFAST ADVISORS LP 105,409 35,983 -65.86 3,311 914 -72.40
2017-05-12 13F-HR NEW YORK LIFE TRUST CO 989 0 -100.00 25 0 -100.00
2018-05-14 13F-HR MONROE BANK & TRUST/MI 918 0 -100.00 23 0 -100.00
2016-11-14 13F-HR EDMOND DE ROTHSCHILD (SUISSE) S.A. 13,731 431
2016-11-14 13F-HR MASON STREET ADVISORS, LLC 62,896 1,976
2018-05-15 13F-HR HBK INVESTMENTS L P Call 100,000 100,000 0.00 1,779 1,625 -8.66
2017-02-10 13F-HR BlackRock Fund Advisors 5,780,081 5,888,335 1.87 181,552 149,623 -17.59
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 3,975,264 4,140,195 4.15 124,863 105,202 -15.75
2018-05-01 13F-HR Alpha Omega Wealth Management LLC 19 19 0.00 0 0
2017-02-14 13F-HR EverPoint Asset Management, LLC 216,000 0 -100.00 6,785 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 108,000 255,100 136.20 1,921 4,145 115.77
2017-04-07 13F-HR CT Financial Advisors LLC 120 0 -100.00 3,049 0 -100.00
2017-05-15 13F-HR R&F Capital Advisors LP 19,896 0 -100.00 506 0
2017-05-12 13F-HR Kernodle & Katon Asset Management Group, LLC 44,086 0 -100.00 1,120 0 -100.00
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 239,200 0 -100.00 6,078 0 -100.00
2018-05-14 13F-HR Toscafund Asset Management LLP 1,850,000 2,675,000 44.59 29,286 43,735 49.34
2017-05-01 13F-HR Spot Trading L.L.C Put 2,200 0 -100.00 56 0
2017-02-10 13F-HR BlackRock Investment Management, LLC 399,239 482,582 20.88 12,540 12,262 -2.22

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Uniti Group: Uncertainty

1h seekingalpha
While WIN drama will continue to rule the short-term price action, UNIT's ability to execute their growth plan will be the key. (1-0)

Uniti Just Can't WIN

2018-07-19 seekingalpha
Uniti Group's shares fell double-digits in Wednesday's trading session after downgrade from Citigroup analyst to a price target of $15.

Uniti Group: Share Dump Opportunity

2018-07-18 seekingalpha
The recent news cycle has Uniti Group (UNIT) slumping to recent lows. All it takes for a high-yielding REIT to slump is news of a big fund unloading shares and a negative call from an influential analyst. The dip caused by the sudden negative sentiment offers another opportunity here. (0-1)

Don't Underscore This REIT Known As CORR

2018-07-16 seekingalpha
CORR has proven that the revenue stream is reliable, even in periods of distress, as long as the assets are critical to the upstream operators. (15-0)

Windstream: Objection!

2018-07-13 seekingalpha
Long-time readers know that I have been following the Windstream Holdings (NASDAQ:WIN) vs. Aurelius Capital case closely. With the trial scheduled just a week and a half away, the end is in sight. The case will determine whether or not WIN is in default and whether or not the Uniti Group (NASDAQ:UNIT) spin-off amounted to a sale-leaseback that violated the indentures of WIN's bonds. (0-1)

CUSIP: 20341J104